【24h】

Pioglitazone: effect on CYP3A4 activity.

机译:吡格列酮:对CYP3A4活性的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical studies demonstrate CYP3A4 enzyme induction with troglitazone, a thiazolidinedione derivative structurally related to pioglitazone. The objective of this prospective, open-label study conducted in healthy volunteers was to evaluate the influence of multiple-dose pioglitazone therapy on the urinary excretion ratio of 6-beta-hydroxycortisol to cortisol, an endogenous marker of CYP3A4 activity. Twelve subjects were given pioglitazone hydrochloride 45 mg daily for 14 days. Urine was collected over a 24-hour period before pioglitazone and after administration of the last tablet. Baseline and posttreatment CYP3A4 activity was assessed with the urinary 6-beta-hydroxycortisol/cortisol ratio. The mean +/- SD 6-beta-hydroxycortisol/cortisol ratios before and after treatment were 8.3 +/- 4.4 and 9.4 +/- 4.0, respectively (p = 0.29). The mean change from baseline was a nonsignificant 20.2%. Nine subjects had a small increase and 3 subjects had a reduction in the ratio. Using the ratio as a marker of CYP3A4 activity, the data support a lack of inductive effect on CYP3A4 by multiple-dose pioglitazone therapy. Thus, administration of pioglitazone should not result in clinically significant effects on the pharmacokinetics of other CYP3A4 substrates.
机译:临床研究表明曲格列酮是CYP3A4酶的诱导剂,曲格列酮是与吡格列酮结构相关的噻唑烷二酮衍生物。在健康志愿者中进行的这项前瞻性,开放性研究的目的是评估多剂量吡格列酮治疗对6-β-羟基皮质醇与皮质醇(一种CYP3A4活性内源性标志物)的尿排泄率的影响。每天给十二名受试者服用盐酸吡格列酮45 mg,持续14天。在吡格列酮治疗前和最后一次服用片剂后的24小时内收集尿液。用尿中的6-β-羟基皮质醇/皮质醇比率评估基线和治疗后CYP3A4的活性。治疗前后的平均+/- SD6-β-羟基皮质醇/皮质醇比分别为8.3 +/- 4.4和9.4 +/- 4.0(p = 0.29)。与基线相比的平均变化不显着20.2%。 9名受试者的比例有所增加,而3名受试者的比例有所降低。使用该比率作为CYP3A4活性的标记,数据支持多剂量吡格列酮治疗对CYP3A4缺乏诱导作用。因此,吡格列酮的给药不应对其他CYP3A4底物的药代动力学产生临床上显着的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号